In the fourth quarter, Flagship Harbor Advisors LLC disclosed in a Securities and Exchange Commission filing that it had sold 44% of its holdings in GlaxoSmithKline (NYE:GSK), a pharmaceutical company. At the end of the reporting period, the firm owned 14,347 shares of GSK valued at $504,000. Other hedge funds, including Arkadios Wealth Advisors, Dorsey & Whitney Trust, O Rourke & Company, Evergreen Capital Management, and Nelson Van Denburg & Campbell Wealth Management Group, also made changes to their positions. GSK’s stock has a consensus rating of “hold” and a price target of $1,576.88. The company recently announced a quarterly dividend of $0.3404, payable on April 13, Thursday.
GSK’s Stock Growth
GSK’s stock has been showing mixed performance, opening at $35.22 on Friday with a 50-day simple moving average of $35.02 and a 200-day simple moving average of $33.64. The pharmaceutical giant has a market capitalization of $75.92 billion, a PE ratio of 4.10, and a beta of 0.65. While GSK has received a “buy” rating from AlphaValue and Goldman Sachs, Citigroup lowered its price target on GSK due to concerns about the recent dividend cut, which resulted in a payout ratio of 15.50%.
GlaxoSmithKline PLC Stock Analysis
The average target price for GlaxoSmithKline PLC ADR over the next 12 months is USD 36.50, according to the consensus of 14 analysts. The average rating for the stock is Hold, while Stock Target Advisor’s analysis indicates a Slightly Bullish outlook based on 3 positive and 2 negative signals. At the time of the last closing, the stock was valued at USD 35.22. Over the past week, the stock has risen by +4.14%, while over the past month and last year it has fallen by -0.11% and -17.92%, respectively.
Company Overview
GSK plc is a global pharmaceutical company that focuses on the development, manufacturing, and distribution of vaccines and specialty medicines to prevent and treat various diseases worldwide. The company operates through four business segments, namely Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. Its portfolio of pharmaceutical products includes medicines for infectious diseases, HIV, immunology, respiratory conditions, and oncology. Founded in 1715 and headquartered in Brentford, UK, the company was previously known as GlaxoSmithKline plc and recently changed its name to GSK plc in May 2022.
